Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of inhaled seralutinib for pulmonary arterial hypertension
MOH_2024-05-09_013408Phase 3Not yet recruiting
- Sponsor
- GB002, Inc.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of seralutinib in pulmonary arterial hypertension (PAH) (2 arms), sponsored by GB002, Inc. Primary endpoint: Long-term safety and tolerability. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2024-05-09_013408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-09_013408.